NCT02477878View on ClinicalTrials.gov

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 14, 2020

Study Completion Date

January 31, 2033

Conditions
LeukemiaMyelodysplastic SyndromesLymphomaMultiple MyelomaHematologic Neoplasms
Interventions
BIOLOGICAL

BPX-501

Biological: T cells transduced with CaspaCIDe suicide gene

DRUG

Rimiducid

Rimiducid administered to treat GVHD

Trial Locations (5)

14263

Roswell Park, Buffalo

30342

BMT Program at Northside Hospital, Atlanta

66205

University of Kansas, Westwood

75390

UT Southwestern Medical Center, Dallas

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY